No pharmaceutical company has filed an IND application disclosed in the public record
Retrieved from Foster, G
For thyroid C-cell tumors specifically, the FDA requires a boxed warningthe agency's strongest safety warningfor several products including semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide extended-release (Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)
W.H.W.T
This is the same directional change sought with FDA-approved therapies like minoxidil, but achieved through a distinct upstream mechanism
That's why we have paid the utmost attention to every last detail, achieving superior palatability and texture, resulting in a delicious shake